PPA
TOVX icon

Parametric Portfolio Associates’s Theriva Biologics TOVX Stock Holding History

Parametric Portfolio Associates’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12
Closed -$55K – 3966
2017
Q4 		$55K Buy
12
+1
+9% +$6.25K ﹤0.01% 3865
2017
Q3 		$86K Buy
+11
New +$63.6K ﹤0.01% 3962
2017
Q2 		– Sell
-9
Closed -$52K – 4032
2017
Q1 		$52K Buy
+9
New +$62.8K ﹤0.01% 3739

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Parametric Portfolio Associates's TOVX Position: Q1 2018 in Review

Parametric Portfolio Associates sold out of Theriva Biologics (TOVX) in Q1 2018, closing a stake of 12 shares — an estimated $55K sold.

Parametric Portfolio Associates first reported a position in TOVX in Q1 2017 and held it in 3 quarters. The position peaked at $86K in Q3 2017. 48 funds tracked by Wall St. Rank hold TOVX as of Q1 2018.

  • Parametric Portfolio Associates reported no remaining Theriva Biologics position as of Q1 2018 after selling out during the quarter.
  • Parametric Portfolio Associates sold 12 Theriva Biologics shares in Q1 2018, an estimated $55K.
  • Parametric Portfolio Associates first reported a position in Theriva Biologics in Q1 2017 and held it in 3 quarters.
  • Parametric Portfolio Associates's Theriva Biologics position peaked at $86K in Q3 2017.
  • 48 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2018.

Based on Parametric Portfolio Associates's 13F filing for Q1 2018, filed 14 May 2018.